A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
Clinical trial NCT04914390 · UNKNOWN
Trial details
- NCT number
- NCT04914390
- Sponsor
- Sichuan Provincial People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-15
- Primary completion
- 2025-03-31
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.